Dae Hwa Pharm Co Ltd

Dae Hwa Pharm Co Ltd has a market capitalization of KRW 229.14 billion and a price-to-earnings ratio of 138.58, indicating a high valuation relative to its earnings. The company's liquidity position is constrained, with a current ratio of 0.51 and only KRW 1.29 billion in cash and equivalents, which is significantly lower than its long-term debt of KRW 96.78 billion. The debt-to-equity ratio of 1.31 suggests a leveraged capital structure, with liabilities exceeding equity by KRW 62.72 billion. The company's profitability metrics are weak compared to industry norms. Return on equity (ROE) is 2.23%, and return on assets (ROA) is 0.78%, both below the typical thresholds for pharmaceutical firms. Operating income of KRW 7.54 billion and net income of KRW 1.65 billion represent margins of 5.27% and 1.15%, respectively, which are below the industry median for profitability. Gross profit of KRW 47.83 billion reflects a margin of 33.43%, which is in line with the industry but does not translate into strong net returns. Dae Hwa Pharm Co Ltd's revenue is concentrated in a single geographic market, South Korea, with no disclosed international operations. The company's business is entirely within the pharmaceuticals segment, with no diversification into medical research or other healthcare subsectors. This lack of geographic and product diversification increases exposure to domestic regulatory and economic risks. The company's revenue growth is modest, with a current fiscal year outlook showing no significant acceleration. Free cash flow of KRW 1.07 billion is insufficient to cover capital expenditures of KRW 4.73 billion, indicating a need for external financing or debt management. The company's operating cash flow of KRW 4.91 billion is positive but not robust enough to support long-term growth without additional capital. Dae Hwa Pharm Co Ltd faces medium liquidity risk due to its low cash reserves and high debt load. The risk assessment highlights a key flag: net cash is negative after subtracting total debt, which could limit the company's ability to respond to short-term obligations. The dilution risk is currently low, with no near-term pressure from share issuance or convertible instruments. However, the company's capital structure may require adjustments if operating cash flow does not improve. Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's focus remains on maintaining its domestic market position and managing its debt obligations. There are no disclosed plans for international expansion or significant R&D investments in the near term.